SCHEMBL63496

SCHEMBL63496

CN(C(=O)c1cccnc1)C12CCC(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.46
CYP2C9 P11712 1/20 0.46
KCNA5 P22460 1/20 0.38
TLR2 O60603 1/20 0.38
CALCA P06881 1/20 0.37
TSHR P16473 2/20 0.36
USP2 O75604 1/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
SCD O00767 1/20 0.36
ERCC1 P07992 1/20 0.36
FEN1 P39748 1/20 0.36
ERCC4 Q92889 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63480 0.91 KCNH2 (0.48) KCNH2CYP2C9CALCASMN1; SMN2ERCC1
SCHEMBL63492 0.91 HCRTR1 (0.38) KCNH2CYP2C9TLR2TSHRUSP2
SCHEMBL52210 0.86 KCNH2 (0.51) KCNH2CYP2C9CALCATSHRMAPK1
SCHEMBL52222 0.86 KCNH2 (0.54) KCNH2CYP2C9CALCATSHRMAPK1
SCHEMBL52473 0.86 KCNH2 (0.43) KCNH2CYP2C9TLR2CALCATSHR
SCHEMBL53197 0.85 CYP2C9 (0.58) KCNH2CYP2C9CALCATSHRMAPK1
SCHEMBL63268 0.83 KCNH2 (0.53) KCNH2CYP2C9CALCATSHRMAPK1
SCHEMBL52503 0.83 KCNH2 (0.46) KCNH2CYP2C9TSHRTP53MAPK1
SCHEMBL52585 0.82 KCNH2 (0.55) KCNH2CYP2C9CALCANPSR1SMN1; SMN2
SCHEMBL10143684 0.82 KCNH2 (0.49) KCNH2CYP2C9CALCATSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885KCNA5 4290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.